A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate (Q43622338)

25 November 2017

title

A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate (English)

1 reference

beclomethasone dipropionate

25 November 2017

1 reference

1 reference

Fairfax A

1

1 reference

25 November 2017

Hall I

series ordinal

2

1 reference

25 November 2017

Spelman R

series ordinal

3

1 reference

25 November 2017

publication date

1 May 2001

1 reference

Annals of Allergy, Asthma & Immunology

25 November 2017

published in

1 reference

25 November 2017

volume

86

1 reference

25 November 2017

issue

5

1 reference

25 November 2017

page(s)

575-582

1 reference

Inflammatory and structural changes in the small airways in bronchial asthma

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Efficacy and safety of inhaled corticosteroids. New developments

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Development of fluticasone propionate and comparison with other inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Improved delivery of inhaled steroids to the large and small airways

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Assessment of airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: potential advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962907-9

7 January 2021

10.1016/S1081-1206(10)62907-9

Identifiers

DOI

1 reference

25 November 2017

1 reference